Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Nephros (NEPH) Notes Payables (2020)

Nephros has reported Notes Payables over the past 2 years, most recently at $340000.0 for Q3 2020.

Quarterly results put Notes Payables at $340000.0 for Q3 2020, changed N/A from a year ago — trailing twelve months through Sep 2020 was $340000.0 (changed N/A YoY), and the annual figure for FY2010 was $500000.0, changed.
Notes Payables for Q3 2020 was $340000.0 at Nephros, up from $278000.0 in the prior quarter.
Over the last five years, Notes Payables for NEPH hit a ceiling of $340000.0 in Q3 2020 and a floor of $278000.0 in Q2 2020.